Uncoupling Protein 2, in Vivo Distribution, Induction upon Oxidative Stress, and Evidence for Translational Regulation*

Claire PecqueurDagger , Marie-Clotilde Alves-GuerraDagger , Chantal GellyDagger , Corinne Lévi-MeyrueisDagger , Elodie CouplanDagger , Sheila Collins§, Daniel RicquierDagger , Frédéric BouillaudDagger , and Bruno MirouxDagger

From the Dagger  CEREMOD (UPR 9078 CNRS), 9 Rue Jules Hetzel, 92190 Meudon, France and the § Department of Psychiatry and Behavioral Sciences and Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710

Received for publication, August 2, 2000, and in revised form, November 26, 2000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Uncoupling protein 2 (UCP2) belongs to the mitochondrial anion carrier family and partially uncouples respiration from ATP synthesis when expressed in recombinant yeast mitochondria. We generated a highly sensitive polyclonal antibody against human UCP2. Its reactivity toward mitochondrial proteins was compared between wild type and ucp2(-/-) mice, leading to non-ambiguous identification of UCP2. We detected UCP2 in spleen, lung, stomach, and white adipose tissue. No UCP2 was detected in heart, skeletal muscle, liver, and brown adipose tissue. The level of UCP2 in spleen mitochondria is less than 1% of the level of UCP1 in brown adipose tissue mitochondria. Starvation and LPS treatments increase UCP2 level up to 12 times in lung and stomach, which supports the hypothesis that UCP2 responds to oxidative stress situations. Stimulation of the UCP2 expression occurs without any change in UCP2 mRNA levels. This is explained by translational regulation of the UCP2 mRNA. We have shown that an upstream open reading frame located in exon two of the ucp2 gene strongly inhibits the expression of the protein. This further level of regulation of the ucp2 gene provides a mechanism by which expression can be strongly and rapidly induced under stress conditions.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

UCP21 belongs to a large family of at least 35 anion carriers that are present in the inner mitochondrial membrane (1). Most of these carriers transport key metabolite substrates such as the malate, oxoglutarate, citrate, or products from the oxidative phosphorylation such as ADP3-, ATP4-, or Pi (for review see Ref. 2). Since the discovery of ucp2 (3, 4) and ucp3 (5-7) genes, a subfamily of mitochondrial carriers, related to the well known UCP1 from brown adipose tissue, has emerged in mammals as well as in plants (8). The deduced coding sequence for UCP2 predicts 59% identity with UCP1, whereas the predicted UCP3 sequence is 72% identical to UCP2.

The common characteristic of these proteins is to uncouple the respiratory chain from ATP synthesis by dissipating the proton electrochemical gradient when overexpressed in yeast mitochondria (for reviews see Refs. 9 and 10). They may also transport anions, like the other mitochondrial carriers, but these substrates are currently unknown. Over the last few years, several physiological roles have been proposed for UCP2, based on the expression of its mRNA upon various physiological conditions (for review see Ref. 11). Genetic studies suggested the novel UCPs might be linked to hyperinsulinemia (4) or to the resting metabolic rate (12) and consequently to the control of body weight. It was also proposed that UCP2 contributes to the inflammatory response and regulates the production of reactive oxygen species from mitochondria (13, 14). Recently, it has been shown that ucp3(-/-) mice exhibited no consistent phenotypic abnormality, despite a reduced proton leak in muscle mitochondria and a higher level of intracellular ROS in muscle. Moreover, double knockout ucp1-ucp3 phenotype was indistinguishable from the single ucp1(-/-) phenotype (15, 16).

One of the main problems encountered in the physiological studies of the new UCPs is the absence of reliable immunological tools to detect the proteins in vivo. More than 100 publications have described variation of UCP2 mRNA, whereas only seven analyses were performed at the protein level (for reviews see Refs. 9 and 10). In the present study, we have addressed this problem by generating antibodies against the complete human UCP2 sequence, rigorously evaluated their specificity and sensitivity, and compared them with commercial antibodies. Mitochondria were prepared either from ucp2(+/+) or ucp2(-/-) mice that were jointly created by the Ricquier and Collins laboratories (17). UCP2 protein was immunodetected without ambiguity in spleen, lung, stomach, and gonadal WAT (gWAT) but not in other tissues. Although UCP2 protein was found in vivo at a low level in spleen, lung, stomach, and WAT mitochondria, its expression was strongly increased upon fasting and LPS treatment in lung and stomach. Analysis of UCP2 mRNA and protein levels in transfected COS cells showed that the translation of UCP2 transcript is strongly inhibited by an upstream ORF in the exon two of the gene.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Chemicals, Media, and Antibodies-- LPS, benzamidine, aprotinin, pepstatin, leupeptin, bestatin, and phenylmethylsulfonyl fluoride, CAPS, Tween 20, bicinchoninic acid kit, rabbit, sheep, and goat horseradish peroxidase-conjugated antibodies were purchased from Sigma. TPCK and mouse UCP2-IP antibody were obtained from Calbiochem. Dulbecco's modified Eagle's medium, fetal calf serum, and LipofectAMINE were purchased from Life Technologies, Inc. NHS-activated Sepharose 4 fast flow and ECL detection kit were purchased from Amersham Pharmacia Biotech. Human UCP2-NP antibody was obtained from Research Diagnostic Inc., and mUCP22-A and hUCP32-A antibodies were from Alpha Diagnostic International (San Antonio, TX), and anti-cytochrome c antibody from Santa Cruz Biotechnology (Santa Cruz, CA).

Animals and Treatments-- All mice were 7-10 weeks old. ucp2(-/-) mice were generated on an mix inbred 129 and C57BL/6J background (17). C57BL/6 mice were purchased from Elevage Janvier (Orleans, France) and were submitted to 24 h of starvation with free access to water or were injected intraperitoneally with 100 µg of LPS from Escherichia coli serotype 0111:B4 (4 mg of LPS/kg of body weight). Control mice were injected with the same volume of PBS. Mice were killed at different times by cervical dislocation. Half of each organ was frozen in liquid nitrogen and kept for RNA preparation, and the other half was immediately taken for the preparation of fresh mitochondria.

Plasmids Construction-- The complete mouse UCP2 transcript was obtained by PCR using the following primers, forward 5' AAAATCAGTATGCGGCCGCCTTCTGCACTCCTGT 3' and reverse 5' TTTCGCTCATTGCGGCCGCCGGGCTTTATGGGTG 3', and then subcloned in a pcDNA3 vector (Invitrogen, Gronioen, Netherlands) after digestion by NotI. The pUCP2-ORF1 was constructed by digestion with the restriction endonuclease HindIII. Mutations of the upstream initiator methionines at positions 123, 159, and 183 were achieved with the Gene Editor kit (Promega, Charbonnières, France) in combination with 2 sense primers 5' GGACACAATAGTATCAACTTTAAGTGTTTC 3' and 5' CCAGCCATTTTCTAGGGAAAATCGAGGGGATCGGGCCTTGGTAGCCACCGGC 3'. Mouse UCP2 cDNA was amplified by PCR using 5' GATCCATATGGTTGGTTTCAAGGCCAC 3' and 5' ATGAAGCTTTCAGAAAGGTGCCTCCC 3' forward and reverse primers, respectively, and was cloned into NdeI and HindIII restriction sites of pMW7 (18), a high copy number expression plasmid closely related to the pET vector family (19).

Rat UCP1, human UCP2 and mouse UCP3 cDNA sequences were also introduced into a pHis17 expression vector ((20) gift of M. Runswick, Dunn Nutrition Center, Cambridge, UK), a derivative of pMW7 that contains six histidines in frame with BamHI, HindIII, and EcoRI restriction sites of the poly-linker. An internal NdeI site of the rat UCP1 cDNA at nucleotide 581 was first disrupted by mutagenesis using the following primer 5' GAGCTGGTGACGTATGACCTCATGAAGG 3' and subcloned into NdeI and EcoRI sites of pHis17. Human UCP2 and UCP3 cDNA were amplified by PCR using 5' GGATCCCATATGGTTGGGTTCAAGGC 3' and 5' AGCAAGCTTCCCCTTGTAGAAGGCTGTG 3' as forward primers and 5' CAGAAGCTTGAAGGGAGCCTCTCGGGA 3' and 5' ATGGAACATATGGTTGGACTGAAGCC 3' as reverse primers. They were both cloned into the NdeI and HindIII sites of pHis17. Fragment of UCP2 cDNA encoding for UCP2-(95-206) peptide was amplified by PCR using 5' GCATGCATATGCGCATTGGCCTCTACGAC 3' and 5' ACTGGAATTCTTTCAGGAGAGTATCTTTG 3' forward and reverse primers, respectively, and subsequently cloned into NdeI and EcoRI sites of pHis17 expression vector. Cloning into the HindIII of pHis17 expression vector added KLHHHHHH amino acid sequence tag to the C terminus of the recombinant protein, and cloning into the EcoRI site added EFHHHHHH sequence tag. All constructs were sequenced on ABI 373A sequencer using the PRISM Bigdye Terminator sequencing kit (PE-Applied Biosystems, Paris, France).

Preparation of RNA and Northern Blot Analysis-- Total RNAs were extracted from frozen tissue as described previously (21) or from transfected cells with a RNeasy kit (Qiagen, Courtaboeuf, France). Northern analysis of 20 µg of total tissue RNA or 5 µg of total cell culture RNA was carried out as described (22) using an alpha -32P-labeled and the complete mouse UCP2 cDNA as probe (GenBankTM accession number U69135). Quantification of UCP2 signal was determined with a Packard instant imager (Packard Instrument Co., Meriden, CT), and the signal was normalized after hybridization of the membrane with an 18 S rRNA probe.

Purification of UCP Proteins and Production of Anti-UCP2 Antibodies-- Fragments of mouse UCP2 and the full-length rat UCP1, human UCP2, and mouse UCP3 were produced as inclusion bodies in the E. coli C41 (DE3) bacterial strain and purified as described previously (23). Proteins were refolded according to Qiagen's protocol and purified in the presence of Fc12 detergent (Anatrace, Maumee, OH) using nickel-nitrilotriacetic acid resin (Qiagen, Courtaboeuf, France) and the Biologic Duo-flow high pressure liquid chromatography system (Bio-Rad). Purified hUCP2 protein was cross-linked to NHS-activated Sepharose 4 fast flow. Three hundred micrograms of purified peptides or proteins were injected in 5 different rabbits, twice within 15 days and 1 month later. Animals were bled 14 days after the last boost. Blood was left 1 h at room temperature and then overnight at 4 °C and centrifuged at 3,000 × g. After inactivation of the complement at 55 °C for 20 min, serum was precipitated with ammonium sulfate according to Ref. 24 and purified by affinity chromatography on 2-ml hUCP2-NHS column as described before (25).

Cell Culture and Transient Transfections-- The simian kidney epithelial cell line, COS-7 cells, was routinely maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Cells were transiently transfected using LipofectAMINE Plus Reagent according to the manufacturer's instructions and harvested 24 h after transfection for UCP2 mRNA and protein analysis.

Isolation of Mitochondria-- All steps were carried out at 4 °C. Fresh tissues were minced in TES buffer (10 mM Tris, pH 7.5, 1 mM EDTA, 250 mM sucrose) supplemented with the following protease inhibitors: 1 mM benzamidine, 4 µg/ml aprotinin, 1 µg/ml pepstatin, 2 µg/ml leupeptin, 5 µg/ml bestatin, 50 µg/ml TPCK, and 0.1 mM phenylmethylsulfonyl fluoride. Minced tissue or COS cells were carefully disrupted in a Thomas's potter at low speed rotation. Unbroken cells and nuclei were removed by centrifugation of the homogenate at 750 × g for 10 min. The supernatant was centrifuged at 10,000 × g for 20 min, and the mitochondrial pellet was resuspended in 1 ml of TES buffer. Mitochondria were submitted to another round of 10 min of centrifugation at 750 and 10,000 × g, respectively. Mitochondrial protein content was assayed by the bicinchoninic acid method according to the manufacturer's protocol.

Western Blot Analysis-- Proteins were first separated on a 12.5% SDS-polyacrylamide and then transferred onto nitrocellulose membrane by liquid electroblotting (Bio-Rad) for 75 min (125 mA per gel) in a buffer containing 10 mM CAPS and 10% methanol, pH 9. Nonspecific binding was achieved by preincubating the membrane with PBS-T (phosphate-buffered saline containing 0.1% Tween 20) supplemented with 5% dried milk for 1 h at room temperature. All antibodies were diluted in PBS-T, 2% dried milk, and incubated overnight at 4 °C. The concentration of the antibodies was carefully optimized according to the signal to noise ratio. After extensive washing of the membrane with PBS-T, appropriate peroxidase conjugate antibody was incubated 1 h at room temperature in PBS-T, 2% dried milk. Bound peroxidase-conjugated antibody was revealed with the enhanced chemiluminescence reagents kit (ECL, Amersham Pharmacia Biotech). Membrane was exposed for 1, 10, and 60 min on Biomax MR Kodak film. Films were digitized by a Nikon Coolpix 950 camera, and signal was quantified using the Image SXM software version 1.61 6P from NCBI. For statistical analysis, samples were compared on the same blot only.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Generation of Highly Sensitive UCP2 Antibodies-- Fragments of the mouse UCP2 and the full-length rat UCP1, human UCP2, and mouse UCP3 were produced as inclusion bodies in the E. coli C41(DE3) bacterial strain (23). Full-length human UCP2 and mUCP2 (amino acid residues 95-206) proteins were purified on nickel columns in the presence of Fc12 detergent and injected into rabbits. Three antisera were obtained, two anti-hUCP2 sera and one anti-mUCP2 (95-206) serum. Table I summarizes the data obtained with all UCP2 antibodies tested in this study. The rUCP1-375-5 serum, an antibody that we raised against the purified rat UCP1 (26), displayed high sensitivity toward UCP1. This antibody could detect only 80 ng of UCP2 inclusion bodies. The mUCP2-IP (Calbiochem), hUCP32-A and mUCP22-A (Alpha Diagnostic) antibodies had a low titer and poor reactivity toward UCP2. Among the anti-peptide antibodies, the hUCP2-NP antibody (Research Diagnostic Int.) was the most sensitive toward UCP2 and was 50 times more selective for UCP2 than either UCP1 or UCP3. However, mUCP2-2/3 and both antibodies we raised against the full-length UCP2, hUCP2-605 and 606, displayed higher sensitivity toward UCP2 than all the other antibodies (Table I).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Sensitivity and specificity of UCP1, UCP2, and UCP3 antibodies

In Vivo Distribution of UCP2-- Since the hUCP2-605 serum we obtained was the most sensitive antibody and equipotent toward human or mouse UCP2, it was selected to investigate UCP2 distribution in mouse tissues. Western blot analysis revealed the presence of UCP2 protein in spleen, stomach, intestine, lung, and white adipose tissue mitochondria; this detection was specific since the 32-kDa band detected by the antibody disappeared in mitochondria from ucp2(-/-) mice (Fig. 1A). Surprisingly, we were unable to detect UCP2 in muscle, heart, liver, and brain mitochondria. Instead, other bands of similar apparent molecular weight appeared in liver, BAT, and especially in brain mitochondria (Fig. 1B). The strong band observed in BAT mitochondria appears to be UCP1 because it disappeared in BAT mitochondria from ucp1(-/-) mice (data not shown (27)). Incidentally, UCP2 did not appear in BAT mitochondria from ucp1(-/-) mice although the ucp2 gene is up-regulated in these mice (data not shown (27, 28)).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 1.   Immunodetection of UCP2 in spleen, stomach, intestine, lung, and gWAT. Mitochondria were prepared either from ucp2(+/+) or ucp2(-/-) mice tissues, and 30 µg of mitochondrial proteins were loaded onto an SDS-12.5% PAGE gel. Western blot analysis was performed using the hUCP2-605 antibody at 0.1 µg/ml (10 min of exposure of the membrane). To confirm that the equivalent amount of proteins were loaded, the same membrane was probed with an anti-cytochrome c antibody. A, positive control: 5 ng of mouse UCP2 inclusion bodies; immunodetection of UCP2 in spleen, stomach, intestine, lung, and gWAT. B, immunoreactivity of the hUCP2-605 antibody in muscle, heart, liver, brain, and BAT mitochondria.

Western blot analysis with hUCP2-606 and mUCP2-2/3 antibodies gave similar results. However, both antibodies recognized more unspecific proteins than hUCP2-605 antibody. All other antibodies tested in this study (Table I) did not reveal any band in vivo and instead some of them detected other proteins of similar molecular weight. The hUCP2-NP antibody reacted strongly toward proteins in liver and kidney mitochondria (Fig. 2A). The rUCP1-375-5, our anti-UCP1 antibody, revealed a faint band in spleen, liver, and, as expected, a strong band in BAT (Fig. 2B). The hUCP32-A antibody reacted with a 30-kDa protein in kidney, liver, and BAT (Fig. 2C). None of these bands disappeared in mitochondria isolated from ucp2(-/-) mice, demonstrating that these antibodies are unable to detect bona fide UCP2 in vivo.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   Tissue blot analysis with other anti-UCPs antibodies. Mitochondria were isolated from tissues of ucp2(+/+) mice or ucp2(-/-) mice and analyzed for their UCP2 content by Western blot. Gels were loaded with 30 µg of mitochondrial proteins except for B where 3 µg of BAT mitochondria were analyzed. Membranes were probed with different antibodies. A, hUCP2-NP (Calbiochem, 1 µg/ml, 10 min of exposure), the most sensitive anti-UCP2 peptide antibody; B, rUCP1-375-5 (0.1 µg/ml, 60 min of exposure), our anti-UCP1 antibody (26) that was reported to detect UCP2 by immunocytochemistry analysis (40, 43); C, hUCP32-A (Alpha Diagnostic Int., 1 µg/ml, 10 min of exposure), an anti-UCP3 antibody that recognizes UCP2 as easily as UCP3 (see Table I).

UCP2 Protein Is Expressed at Low Level in Vivo-- Quantitative analysis showed that UCP2 was 4 and 10 times less abundant in lung and stomach, respectively, than in spleen mitochondria (p < 0.001, Table II). To estimate the amount of UCP2 protein expressed in vivo, we took advantage of the cross-reactivity of hUCP2-605 antibody toward UCP1. As shown in Fig. 3, 1 µg of BAT mitochondria produced about the same signal in Western blot than 20 µg of spleen mitochondria. The same experiment was repeated five times with mitochondria from different mice. Quantification of the signals led us to the conclusion that the hUCP2-605 antibody reacted 19-fold more toward BAT mitochondria than spleen mitochondria (19 ± 2; n = 5). Since the signal detected in BAT corresponded to UCP1 and given that the hUCP2-605 antibody was 8-fold more sensitive toward UCP2 than UCP1 (Table I), we concluded that UCP2 is ~160-fold less abundant in spleen mitochondria than UCP1 is in BAT mitochondria.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Expression of UCP2 in mouse tissues


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 3.   Quantitative comparison between UCP1 level in BAT and the level of UCP2 in spleen mitochondria. Increasing amount of spleen and BAT mitochondrial proteins were loaded on SDS-12.5% PAGE. The membrane was probed with hUCP2-605 antibody at 0.1 µg/ml to detect UCP2 in spleen and UCP1 in BAT mitochondria (15 min of exposure).

UCP2 Protein Is Increased in Lung and Stomach upon Fasting and LPS Treatment-- It has been previously reported that fasting and LPS treatment increased the level of UCP2 mRNA in skeletal muscle and liver mitochondria, respectively (29-32). Therefore, C57BL/6 mice were either treated with LPS (injected intraperitoneally with 100 µg of LPS or PBS buffer) or fasted for 24 h, and several organs were analyzed for their UCP2 protein content. Following 24 h of fasting, UCP2 remained undetectable in muscle and constant in spleen mitochondria, but a 6-fold increase of UCP2 protein was observed in stomach and lung mitochondria (Fig. 4, A and B). Two LPS-treated mice and two PBS-treated mice were killed 6, 8, 10, 12, 14 (3 mice), 18, and 24 h after injection. Western blot analysis showed that UCP2 protein appears 10 h after LPS injection only in lung mitochondria and reaches its maximal level 2 h later. UCP2 protein returned to its basal expression level 24 h after injection (Fig. 5, A and B). No change in UCP2 protein was observed in the control mice treated with PBS (Fig. 5B) and in stomach, liver, duodenum, kidney, heart, muscle, and spleen of LPS-treated mice. Quantitative analysis of LPS stimulation revealed that UCP2 protein increased 12-fold in lung mitochondria 14 h after injection (p < 0.001, Table II). To assess whether the apparent increase of UCP2 protein in lung mitochondria could simply reflect an increase of UCP2 protein stability, 280 µg of cycloheximide, an inhibitor of protein translation, was also injected intraperitoneally in four mice 9.5 h after LPS injection. Two and one-half hours later all mice were killed and analyzed for their UCP2 content in lung mitochondria. Cycloheximide treatment completely abolished UCP2 stimulation observed 12 h after LPS injection (98.2% inhibition p < 0.001, Table II). This experiment showed that LPS treatment stimulates the de novo synthesis of UCP2 protein in lung.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Increase of UCP2 protein level in stomach and lung upon fasting. Stomach (A) and lung (B) mitochondria were isolated from three 24-h fasting mice and three control mice. 30 µg of mitochondrial proteins were loaded on SDS-12.5% PAGE and analyzed by Western blot. UCP2 protein was revealed using hUCP2-605 antibody at 0.1 µg/ml. Northern blot analysis: RNA (20 µg) were prepared from stomach (C) and lung (D) of the same animals used for the preparation of mitochondrial proteins. The full-length UCP2 cDNA was used as probe. UCP2 signal was quantified after hybridization of the membrane with 18 S rRNA probe.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Induction of UCP2 protein in mouse lung mitochondria after LPS injection. Mitochondria (30 µg) from two LPS- or PBS-treated mice were prepared 6, 8, 10, 12, 14 (3 mice), 20, and 24 h after LPS injection. A, immunodetection of UCP2 using hUCP2-605 antibody at 0.1 µg/ml (10 min of exposure). B, graphic representation of UCP2 protein induction: closed circle, LPS-treated mice; open circle, PBS-treated mice. Level of UCP2 in lung mitochondria of noninjected mouse was chosen as reference. C, Northern blot analysis: total RNA (10 µg) were prepared from one lung of control mice or LPS-treated mice. The full-length UCP2 cDNA was used as probe. UCP2 signal was quantified after hybridization of the membrane with 18 S rRNA probe.

UCP2 mRNA Levels Do Not Reflect UCP2 Protein Content in Mitochondria-- To investigate whether the fluctuations in the protein content correlated with gene expression, total RNAs were prepared, and UCP2 mRNA level was estimated by Northern blot analysis. Although UCP2 protein level was 4 and 10 times lower in lung and stomach, respectively, than in spleen mitochondria, UCP2 mRNA levels in those tissues were very similar (Table II). The same discrepancy between UCP2 protein and mRNA levels was observed in stimulated conditions. The levels of UCP2 mRNA in lung and stomach marginally increased upon fasting (Fig. 4, C and D, and Table II). UCP2 mRNA levels also remained surprisingly unchanged over the LPS time course experiment (Fig. 5C). Fourteen hours after LPS injection, UCP2 mRNA levels in spleen and lung were comparable, although UCP2 protein content in lung had increased 12 times to reach three times the basal level of UCP2 in spleen (Table II). Finally, despite the strong variations of UCP2 protein that were observed in basal or stimulated conditions, the level of UCP2 mRNA did not correlate with the amount of UCP2 protein.

An Open Reading Frame in the Exon 2 of ucp2 Gene Inhibits the Translation of the Protein-- The striking difference between the abundance of UCP2 mRNA and the tiny amount of UCP2 protein detected in mitochondria as well as the discrepancy between UCP2 mRNA and protein levels prompted us to investigate whether expression was regulated at the translational level. We have shown that ucp2 gene contained a short open reading frame (ORF1) in exon 2 which potentially encodes a putative peptide of 36 amino acids (33) (Fig. 6A). Although the translation of UCP2 protein was not affected by the ORF1 in reticulocyte lysate (33), we examined whether its presence could influence the expression of UCP2 in transiently transfected COS cells. COS cells were transfected with the pcDNA3 expression plasmid, encoding the complete mUCP2 cDNA sequence or the same construct lacking the ORF1 sequence. The three methionine residues in ORF1 were also mutated into serine residues (Fig. 6A). Due to the polyadenylation tail of the pcDNA3 vector, recombinant UCP2 mRNA had a higher apparent molecular weight than mouse UCP2 mRNA (Fig. 6B). Although UCP2 mRNA level was 56 times higher in cells transfected with pUCP2 construct than in mouse spleen, the amount of UCP2 protein was only 3.5 times higher in COS cell mitochondria than in spleen mitochondria (Fig. 6B and Table III). Thus, the coupling between transcription and translation of ucp2 gene is more efficient in mouse spleen than in transfected COS cells. However, transfection of COS cells with pUCP2-ORF1 or pUCP2-ATG increased the production of UCP2 protein 50 and 17 times, respectively, in COS cell mitochondria, without major changes in UCP2 mRNA levels (Fig. 6, B and C). In the absence of ORF1, UCP2 protein content in COS cell mitochondria reached up to 176 times the level of UCP2 in spleen mitochondria, although the UCP2 mRNA level had increased only 28 times (Table III). These results demonstrated that the ATGs present in ORF1 strongly inhibits the translation of UCP2 mRNA and supports the lack of correlation between UCP2 mRNA levels and protein content observed in mouse tissues.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 6.   An upstream ORF in exon two of the gene inhibits the translation of UCP2. A, amino acid sequence of ORF1 peptide is enlarged; the three methionines are marked in bold and underlined. Roman numerals indicate the exons in UCP2 cDNA inserted into pcDNA3 vector. Punctual mutations of ATG codons in the pUCP2-ATG construct are indicated in bold and underlined. B, Northern blot and Western blot analysis of UCP2 expression after transfection of COS cells. Upper panel, 20 µg of spleen RNA and 5 µg of transfected COS cells RNA were analyzed by Northern blot. Lower panel, Western blot analysis of UCP2 expression was performed using the hUCP2-605 antibody (0.1 µg/ml, 1 min of exposure) and using 30 µg of spleen mitochondria protein and 6 µg of mitochondria protein from transfected COS cells. C, graphic representation of UCP2 protein and mRNA levels. Cells transfected with pUCP2 expression vector were chosen as references for UCP2 protein and mRNA levels. Data are given as percentage of pUCP2. Bar and error bar correspond to mean ± S.E.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Regulation of UCP2 expression in recombinant COS cells

UCP3, BMCP1, and Other Mitochondrial Carriers Contain Upstream ORF-- The 5'-untranslated region of all known mammalian mitochondrial carriers was analyzed for the presence of upstream AUG or ORF. Among the 33 human and rodent cDNA sequences available, 9 of them contained at least one upstream AUG or ORF. We found that ucp3 and bmcp1 also contained 1 and 3 ORFs, respectively (Table IV). Statistical parameters developed by Kochetov et al. (34) were used to predict translational efficiency of these mitochondrial carriers. Messenger RNA that are weakly translated generally possess a long 5'-UTR (more than 50 nucleotides), a G + C content in their 5'-UTR around 60%, and a context of complementary nucleotides given by the A/U ratio between 0.75 and 1.25. In addition to their upstream ORF, the five mitochondrial carriers that contained upstream ORFs fulfilled at least two out of the three conditions described above (Table IV). These results indicate that ucp3 and bmcp1 are probably subject to translational regulation and, consequently, are poorly expressed in vivo.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Mitochondrial carrier with an upstream ORF


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Immunodetection of UCP2-- Several attempts were made to identify in vivo UCP2 protein. Peptide antibodies (35-37), antibodies against the full-length UCP2 (38), or anti-UCP1 antibodies (14, 39, 40) were employed to detect the protein either by Western blot or immunocytochemistry analysis (41-44). The identification of UCP1, UCP2, or UCP3 was established by correlation with the tissue distribution of the mRNA. It was also advocated that competition with synthetic peptides and the apparent molecular weight confirmed the identification of the bands as UCP1, UCP2, or UCP3 (38, 45). These arguments are not sufficient to identify the UCPs in vivo since most of the anti-UCP antibodies cross-react with other proteins. This is especially true in liver mitochondria since four antibodies tested in this study detected nonspecific bands (Figs. 1 and 2). We also tested the N-terminal UCP2 antibody (Santa Cruz Biotechnology) that has been used by Diehl's group (35, 37). One strong nonspecific band was detected in liver mitochondria around 32 kDa (data not show). To reconcile biochemical data previously observed in liver and our immunological data, one could speculate that there is another member of the UCP family, specifically expressed in liver mitochondria, that might have a similar function than UCP2. Our hUCP2-605 antibody also shows a moderate specificity. Therefore, mitochondria from tissues of ucp2(-/-) mice were essential to identify the protein in vivo. By doing so, we demonstrated that UCP2 protein is undoubtedly expressed in spleen, lung, stomach, and gWAT mitochondria. Regarding the other tissues, UCP2 protein might be present at very low levels, expressed only in some subset of cells or simply not expressed. For instance, although UCP2 mRNA has a neuronal localization by in situ hybridization, its distribution is not uniform in the brain, and the mRNA is especially abundant in the suprachiasmatic nucleus and other nuclei (46).

Translational Regulation of UCP2 Expression-- Several lines of evidence support the possibility that UCP2 mRNA does not correlate with the variation of the protein. First, UCP2 protein is 10 times less expressed in stomach mitochondria than in spleen even if the relative amount of UCP2 mRNA in both organs is similar (Table II). Second, the increase of UCP2 protein in lung and stomach upon fasting or LPS treatment is not accompanied by an increase of UCP2 mRNA. Third, inactivation of ORF1 in ucp2 gene increased 50 times the expression of UCP2 protein in transfected COS cells without any major changes at the mRNA level. Cotransfection of COS cells with a vector encoding ORF1 peptide and pUCP2-ATG did not repress the expression of the UCP2 protein, and disruption of the first or the second ATG of the upstream ORF also stimulated the expression of UCP2 (data not shown). Thus, the ucp2 gene is down-regulated in cis at translational level by an upstream ORF. These results do not exclude transcriptional regulation of the ucp2 gene. UCP2 mRNA is highly expressed in spleen, lung, stomach, and WAT but is weakly expressed in the other tissues. Since UCP2 protein was found only in tissues where the its mRNA was highly abundant, it is possible that the tissue specificity of ucp2 gene expression is partially controlled at the transcriptional level, whereas the level of UCP2 protein is modulated by translational regulation. The molecular mechanism by which UCP2 protein synthesis is suddenly stimulated in vivo remains unclear. Reverse transcriptase PCR analysis (between exon 1 and 4) during the LPS time course experiment did not reveal an alternative splicing of UCP2 exon 2 explaining the increase of UCP2 protein in lung (data not shown). Therefore, it is likely that most of the ribosomes initiate the translation at the first ORF1 AUGs, and only few of them initiate the translation at the downstream UCP2 AUG.

It is intriguing that all newly discovered UCPs also contain upstream ORF. Since a discrepancy between mRNA and protein expression has been also suggested for UCP3 by Sivitz et al. (45), one should be very cautious about mRNA variations of UCP2, UCP3, or BMCP1. For instance, Cadenas et al. (47) and Matthias et al. (28) conducted extensive bioenergetic studies on starved rat muscle mitochondria and BAT mitochondria from UCP1-ablated mice, respectively. They showed that although ucp2 gene transcription was strongly up-regulated, mitochondrial proton conductance remained unchanged. In our hands UCP2 protein remained undetectable in the BAT of Ucp1(-/-) mice. Given the translational regulation of ucp2 gene, it is possible that UCP2 mRNA levels do not always reflect the expression of the protein itself.

Physiological Aspects-- It is admitted that UCP1 is a slow proton transporter highly expressed in brown adipose tissue mitochondria. In cold-adapted rat, UCP1 protein reaches up to 5% of mitochondrial proteins (48), and its thermogenic contribution relies on its abundance and its activation by free fatty acids. After LPS stimulation, UCP2 protein increases in lung but reaches only 0.02% of the mitochondrial proteins, suggesting that either both proteins do not work the same way or they do not have the same function. On one hand, since UCP2 and UCP3 are weakly inhibited by purine nucleotides (49-51), it is possible that UCP2 is constantly activated in vivo whereas UCP1 is always inhibited by nucleotides in BAT mitochondria. On the other hand, one could also propose that the function of the new UCPs is not to trigger thermogenesis by a strong mitochondrial uncoupling. Negre-Salvayre et al. (14), Lee et al. (13), and Yang et al. (37) have proposed that UCP2 regulates the production of reactive oxygen species by uncoupling the respiratory chain, as suggested by Skulachev (52). In fact, studies on ucp3(-/-) mice (16) and ucp2(-/-) mice (17) showed that both proteins do indeed regulate the production of ROS since higher levels of ROS were observed in muscle and macrophage, respectively. The finding that UCP2 is increased in lung and stomach upon LPS treatment and starvation also support this hypothesis. The kinetics of induction of UCP2 protein after LPS injection is consistent with a primary immune response leading to an oxidative burst in lung. Activation of macrophage receptors by LPS stimulate the production of proinflammatory cytokines such as TNFalpha (53) which activates the NF-kappa B pathway. The cellular content of reduced glutathione decreases, and consequently, the level of intracellular ROS increases (for review see Ref. 54). Since starvation has also been shown to provoke a marked decrease of reduced glutathione level in lung (54) and in stomach (55), one could propose that UCP2 does not have any function in basal conditions but is up-regulated when the level of intracellular reactive oxygen species is too high. In this context, translational regulation of UCP2 might ensure a rapid cellular response, based on the large pool of UCP2 mRNA available. Finally, our data point out the lung and the stomach as two major organs where UCP2 plays an important role. Since both organs are constantly exposed to toxic compounds and pathogens, the natural function of UCP2 might be to protect the organism from oxidative stresses provoked by infection, allergy, or pollution.

    ACKNOWLEDGEMENTS

We are grateful to Hiroki Onuma for work in characterizing the ucp2(-/-) mice; L. P. Kozak for the gift of ucp1(-/-) mice; M. Runswick and J. E. Walker for the pHis17 expression vector; D. Sanchis for the cloning of mouse UCP3 cDNA; M. Marsolo and A. Pigenet for technical assistance; and K. Marheineke for critical reading of the manuscript.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: CNRS-CEREMOD, 9 Rue Jules Hetzel, 92190 Meudon, France. Tel.: 00 33 1 45 07 57 47; Fax: 00 33 1 45 07 58 90; E-mail: bmiroux{at}infobiogen.fr.

Published, JBC Papers in Press, November 29, 2000, DOI 10.1074/jbc.M006938200

    ABBREVIATIONS

The abbreviations used are: UCPs, uncoupling protein 1, 2, and 3; BMCP1, brain mitochondrial carrier protein; BAT, brown adipose tissue; gWAT, gonadal white adipose tissue; LPS, lipopolysaccharide; Fc12, Fos-choline 12 (N-dodecylphosphocholine); UTR, untranslated region; ORF, open reading frame; TPCK, L-tosylamido-2-phenylethyl chloromethyl ketone; CAPS, 3-(cyclohexylamino)-1-propanesulfonic acid; ROS, reactive oxygen species; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; NHS, N-hydroxysuccinimide.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. El Moualij, B., Duyckaerts, C., Lamotte-Brasseur, J., and Sluse, F. E. (1997) Yeast 13, 573-581[CrossRef][Medline] [Order article via Infotrieve]
2. Kramer, R., and Palmieri, F. (1989) Biochim. Biophys. Acta 974, 1-23[Medline] [Order article via Infotrieve]
3. Gimeno, R. E., Dembski, M., Weng, X., Deng, N., Shyjan, A. W., Gimeno, C. J., Iris, F., Ellis, S. J., Woolf, E. A., and Tartaglia, L. A. (1997) Diabetes 46, 900-906[Abstract]
4. Fleury, C., Neverova, M., Collins, S., Raimbault, S., Champigny, O., Levi-Meyrueis, C., Bouillaud, F., Seldin, M. F., Surwit, R. S., Ricquier, D., and Warden, C. H. (1997) Nat. Genet. 15, 269-272[Medline] [Order article via Infotrieve]
5. Gong, D. W., He, Y., Karas, M., and Reitman, M. (1997) J. Biol. Chem. 272, 24129-24132[Abstract/Free Full Text]
6. Vidal-Puig, A., Solanes, G., Grujic, D., Flier, J. S., and Lowell, B. B. (1997) Biochem. Biophys. Res. Commun. 235, 79-82[CrossRef][Medline] [Order article via Infotrieve]
7. Boss, O., Samec, S., Paoloni-Giacobino, A., Rossier, C., Dulloo, A., Seydoux, J., Muzzin, P., and Giacobino, J. P. (1997) FEBS Lett. 408, 39-42[CrossRef][Medline] [Order article via Infotrieve]
8. Laloi, M., Klein, M., Riesmeier, J. W., Muller-Rober, B., Fleury, C., Bouillaud, F., and Ricquier, D. (1997) Nature 389, 135-136[CrossRef][Medline] [Order article via Infotrieve]
9. Boss, O., Hagen, T., and Lowell, B. B. (2000) Diabetes 49, 143-156[Abstract]
10. Ricquier, D., and Bouillaud, F. (2000) Biochem. J. 345, 161-179[CrossRef][Medline] [Order article via Infotrieve]
11. Fleury, C., and Sanchis, D. (1999) Int. J. Biochem. Cell Biol. 31, 1261-1278[CrossRef][Medline] [Order article via Infotrieve]
12. Bouchard, C., Perusse, L., Chagnon, Y. C., Warden, C., and Ricquier, D. (1997) Hum. Mol. Genet. 6, 1887-1889[Abstract/Free Full Text]
13. Lee, F. Y., Li, Y., Zhu, H., Yang, S., Lin, H. Z., Trush, M., and Diehl, A. M. (1999) Hepatology 29, 677-687[Medline] [Order article via Infotrieve]
14. Negre-Salvayre, A., Hirtz, C., Carrera, G., Cazenave, R., Troly, M., Salvayre, R., Penicaud, L., and Casteilla, L. (1997) FASEB. J. 11, 809-815[Abstract/Free Full Text]
15. Gong, D. W., Monemdjou, S., Gavrilova, O., Leon, L. R., Marcus-Samuels, B., Chou, C. J., Everett, C., Kozak, L. P., Li, C., Deng, C., Harper, M. E., and Reitman, M. L. (2000) J. Biol. Chem. 275, 24129-24132
16. Vidal-Puig, A. J., Grujic, D., Zhang, C. Y., Hagen, T., Boss, O., Ido, Y., Szczepanik, A., Wade, J., Mootha, V., Cortright, R., Muoio, D. M., and Lowell, B. B. (2000) J. Biol. Chem. 275, 16258-16266[Abstract/Free Full Text]
17. Arsenijevic, D., Onuma, H., Pecqueur, C., Raimbault, S., Manning, B. S., Miroux, B., Goubern, M., Alves-Guerra, M., Couplan, E., Surwit, R., Bouillaud, F., Richard, D., Collins, S., and Ricquier, D. (2000) Nat. Genet. 26, 435-439[CrossRef][Medline] [Order article via Infotrieve]
18. Way, M., Pope, B., Gooch, J., Hawkins, M., and Weeds, A. G. (1990) EMBO J. 9, 4103-4109[Abstract]
19. Studier, F. W., Rosenberg, A. H., Dunn, J. J., and Dubendorff, J. W. (1990) Methods Enzymol. 185, 60-89[Medline] [Order article via Infotrieve]
20. Lowe, J., and Amos, L. A. (1998) Nature 391, 203-206[CrossRef][Medline] [Order article via Infotrieve]
21. Ricquier, D., Bouillaud, F., Toumelin, P., Mory, G., Bazin, R., Arch, J., and Penicaud, L. (1986) J. Biol. Chem. 261, 13905-13910[Abstract/Free Full Text]
22. Cassard, A. M., Bouillaud, F., Mattei, M. G., Hentz, E., Raimbault, S., Thomas, M., and Ricquier, D. (1990) J. Cell. Biochem. 43, 255-264[Medline] [Order article via Infotrieve]
23. Miroux, B., and Walker, J. E. (1996) J. Mol. Biol. 260, 289-298[CrossRef][Medline] [Order article via Infotrieve]
24. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual , pp. 298-299, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
25. Miroux, B., Casteilla, L., Klaus, S., Raimbault, S., Grandin, S., Clement, J. M., Ricquier, D., and Bouillaud, F. (1992) J. Biol. Chem. 267, 13603-13609[Abstract/Free Full Text]
26. Ricquier, D., Barlet, J. P., Garel, J. M., Combes-George, M., and Dubois, M. P. (1983) Biochem. J. 210, 859-866[Medline] [Order article via Infotrieve]
27. Enerback, S., Jacobsson, A., Simpson, E. M., Guerra, C., Yamashita, H., Harper, M. E., and Kozak, L. P. (1997) Nature 387, 90-94[CrossRef][Medline] [Order article via Infotrieve]
28. Matthias, A., Jacobsson, A., Cannon, B., and Nedergaard, J. (1999) J. Biol. Chem. 274, 28150-28160[Abstract/Free Full Text]
29. Boss, O., Samec, S., Dulloo, A., Seydoux, J., Muzzin, P., and Giacobino, J. P. (1997) FEBS Lett. 412, 111-114[CrossRef][Medline] [Order article via Infotrieve]
30. Faggioni, R., Shigenaga, J., Moser, A., Feingold, K. R., and Grunfeld, C. (1998) Biochem. Biophys. Res. Commun. 244, 75-78[CrossRef][Medline] [Order article via Infotrieve]
31. Cortez-Pinto, H., Yang, S. Q., Lin, H. Z., Costa, S., Hwang, C. S., Lane, M. D., Bagby, G., and Diehl, A. M. (1998) Biochem. Biophys. Res. Commun. 251, 313-319[CrossRef][Medline] [Order article via Infotrieve]
32. Busquets, S., Sanchis, D., Alvarez, B., Ricquier, D., Lopez-Soriano, F. J., and Argiles, J. M. (1998) FEBS Lett. 440, 348-350[CrossRef][Medline] [Order article via Infotrieve]
33. Pecqueur, C., Cassard-Doulcier, A. M., Raimbault, S., Miroux, B., Fleury, C., Gelly, C., Bouillaud, F., and Ricquier, D. (1999) Biochem. Biophys. Res. Commun. 255, 40-46[CrossRef][Medline] [Order article via Infotrieve]
34. Kochetov, A. V., Ischenko, I. V., Vorobiev, D. G., Kel, A. E., Babenko, V. N., Kisselev, L. L., and Kolchanov, N. A. (1998) FEBS Lett. 440, 351-355[CrossRef][Medline] [Order article via Infotrieve]
35. Chavin, K. D., Yang, S., Lin, H. Z., Chatham, J., Chacko, V. P., Hoek, J. B., Walajtys-Rode, E., Rashid, A., Chen, C. H., Huang, C. C., Wu, T. C., Lane, M. D., and Diehl, A. M. (1999) J. Biol. Chem. 274, 5692-5700[Abstract/Free Full Text]
36. Simoneau, J. A., Kelley, D. E., Neverova, M., and Warden, C. H. (1998) FASEB. J. 12, 1739-1745[Abstract/Free Full Text]
37. Yang, S., Zhu, H., Li, Y., Lin, H., Gabrielson, K., Trush, M. A., and Diehl, A. M. (2000) Arch. Biochem. Biophys. 378, 259-268[CrossRef][Medline] [Order article via Infotrieve]
38. Jezek, P., Zackova, M., Rehakova, Z., Ruzicka, M., Borecky, J., Skobisova, E., Brucknerova, J., Garlid, K. D., Gimeno, R. E., and Tartaglia, L. A. (1999) FEBS Lett. 455, 79-82[CrossRef][Medline] [Order article via Infotrieve]
39. Liu, Q., Bai, C., Chen, F., Wang, R., MacDonald, T., Gu, M., Zhang, Q., Morsy, M. A., and Caskey, C. T. (1998) Gene (Amst.) 207, 1-7[CrossRef][Medline] [Order article via Infotrieve]
40. Larrouy, D., Laharrague, P., Carrera, G., Viguerie-Bascands, N., Levi-Meyrueis, C., Fleury, C., Pecqueur, C., Nibbelink, M., Andre, M., Casteilla, L., and Ricquier, D. (1997) Biochem. Biophys. Res. Commun. 235, 760-764[CrossRef][Medline] [Order article via Infotrieve]
41. Rashid, A., Wu, T. C., Huang, C. C., Chen, C. H., Lin, H. Z., Yang, S. Q., Lee, F. Y., and Diehl, A. M. (1999) Hepatology 29, 1131-1138[Medline] [Order article via Infotrieve]
42. Qian, H., Hausman, G. J., Compton, M. M., Azain, M. J., Hartzell, D. L., and Baile, C. A. (1998) Biochem. Biophys. Res. Commun. 246, 660-667[CrossRef][Medline] [Order article via Infotrieve]
43. Hodny, Z., Kolarova, P., Rossmeisl, M., Horakova, M., Nibbelink, M., Penicaud, L., Casteilla, L., and Kopecky, J. (1998) FEBS Lett. 425, 185-190[CrossRef][Medline] [Order article via Infotrieve]
44. Cortez-Pinto, H., Lin, H. Z., Yang, S. Q., Odwin Da Costa, S., and Diehl, A. M. (1999) Gastroenterology 116, 1184-1193[Medline] [Order article via Infotrieve]
45. Sivitz, W. I., Fink, B. D., and Donohoue, P. A. (1999) Endocrinology 140, 1511-1519[Abstract/Free Full Text]
46. Richard, D., Rivest, R., Huang, Q., Bouillaud, F., Sanchis, D., Champigny, O., and Ricquier, D. (1998) J. Comp. Neurol. 397, 549-560[CrossRef][Medline] [Order article via Infotrieve]
47. Cadenas, S., Buckingham, J. A., Samec, S., Seydoux, J., Din, N., Dulloo, A. G., and Brand, M. D. (1999) FEBS Lett. 462, 257-260[CrossRef][Medline] [Order article via Infotrieve]
48. Ricquier, D., Mory, G., Bouillaud, F., Thibault, J., and Weissenbach, J. (1984) FEBS Lett. 178, 240-244[CrossRef][Medline] [Order article via Infotrieve]
49. Jaburek, M., Varecha, M., Gimeno, R. E., Dembski, M., Jezek, P., Zhang, M., Burn, P., Tartaglia, L. A., and Garlid, K. D. (1999) J. Biol. Chem. 274, 26003-26007[Abstract/Free Full Text]
50. Echtay, K. S., Liu, Q., Caskey, T., Winkler, E., Frischmuth, K., Bienengraber, M., and Klingenberg, M. (1999) FEBS Lett. 450, 8-12[CrossRef][Medline] [Order article via Infotrieve]
51. Rial, E., Gonzalez-Barroso, M., Fleury, C., Iturrizaga, S., Sanchis, D., Jimenez-Jimenez, J., Ricquier, D., Goubern, M., and Bouillaud, F. (1999) EMBO J. 18, 5827-5833[Abstract/Free Full Text]
52. Skulachev, V. P. (1998) Biochim. Biophys. Acta 1363, 100-124[Medline] [Order article via Infotrieve]
53. Ryan, L. K., Golenbock, D. T., Wu, J., and Vermeulen, M. W. (1997) In Vitro Cell Dev. Biol. 33, 647-653
54. Smith, L. J., and Anderson, J. (1992) Am. Rev. Respir. Dis. 146, 1452-1457[Medline] [Order article via Infotrieve]
55. Yegen, B., Dedeoglu, A., Aykac, I., Oktay, S., and Yalcin, A. S. (1990) Pharmacol. Res. 22, 45-48
56. Yoshitomi, H., Yamazaki, K., and Tanaka, I. (1998) Gene (Amst.) 215, 77-84[CrossRef][Medline] [Order article via Infotrieve]
57. Solanes, G., Vidal-Puig, A., Grujic, D., Flier, J. S., and Lowell, B. B. (1997) J. Biol. Chem. 272, 25433-25436[Abstract/Free Full Text]
58. Sanchis, D., Fleury, C., Chomiki, N., Goubern, M., Huang, Q., Neverova, M., Gregoire, F., Easlick, J., Raimbault, S., Levi-Meyrueis, C., Miroux, B., Collins, S., Seldin, M., Richard, D., Warden, C., Bouillaud, F., and Ricquier, D. (1998) J. Biol. Chem. 273, 34611-34615[Abstract/Free Full Text]
59. Zarrilli, R., Oates, E. L., McBride, O. W., Lerman, M. I., Chan, J. Y., Santisteban, P., Ursini, M. V., Notkins, A. L., and Kohn, L. D. (1989) Mol. Endocrinol. 3, 1498-1505[Abstract]
60. Kaplan, R. S., Mayor, J. A., and Wood, D. O. (1993) J. Biol. Chem. 268, 13682-13690[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.